UroGen Downgrade After FDA Setback For Bladder Cancer Drug – UroGen Pharma (NASDAQ:URGN)
HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the rating on UroGen Pharma Ltd. URGN from Buy to Neutral. Selvaraju points out that the FDA’s Oncologic Drugs Advisory Committee voted 5-4 against the benefit-risk profile of UroGen’s investigational therapy UGN-102 (mitomycin for […]
UroGen Downgrade After FDA Setback For Bladder Cancer Drug – UroGen Pharma (NASDAQ:URGN) Read More »